Coca Cola HBC AG (LSE:CCH) | RNS | Coca-Cola HBC AG - 2020 integrated annual report Adapt to Win proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd: Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
1 on a single platform to optimise space and resources in small to medium laboratory settings
With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests
2 across a wide-range of disease areas including infectious diseases, oncology and cardiology
Through automation of manual tasks, Roche s new solution is designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care
F. Hoffmann-La Roche Ltd
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
cobas® pure integrated solutions brings together three diagnostic technologies
1 on a single platform to optimise space and resources in small to medium laboratory settings
With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests
2 across a wide-range of disease areas including infectious diseases, oncology and cardiology
Through automation of manual tasks, Roche’s new solution is designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care
Search jobs 17-Mar-2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
cobas® pure integrated solutions brings together three diagnostic technologies
1 on a single platform to optimise space and resources in small to medium laboratory settings
With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests
2 across a wide-range of disease areas including infectious diseases, oncology and cardiology
Through automation of manual tasks, Roche’s new solution is designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care
Roche Annual General Meeting 2021
All proposals of the Board of Directors approved
Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected
34th consecutive dividend increase to CHF 9.10 per share
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the pandemic restrictions, the AGM was held with only those persons required by the Articles of Incorporation in attendance and with no shareholders physically present. Roche shareholders were able to exercise their rights via written or electronically submitted instructions to the independent proxy, Testaris AG. The independent proxy represented 84.58% of the total of 160,000,000 shares. The Management Report, the Annual Financial Statements and the Consolidated Financial Statements for 2020 were approved.